PubMed
ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves neuropathic symptoms in patients with sarcoidosis
Dahan et al., 2013
Neurological & CognitiveInvestigational (Phase 2)C
ARA-290
Cibinetide
Non-erythropoietic peptide studied for neuropathic and inflammatory indications.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 4
- Research grade
- C
- Experience
- 70
- Activity
- 100
Overall check-ins
Trackers & reports
Overview
About ARA-290
Non-erythropoietic peptide studied for neuropathic and inflammatory indications.
- Category
- Neurological & Cognitive
- Regulatory status
- Investigational (Phase 2)
- Also known as
- Cibinetide
- Self-reports
- 6
Community
What 6 users report
6 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 33% · Mixed 67% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Appetite
6
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Injection site irritation
4
Self-reported dose per injection
Median bucket: 2+ mg · Most common: 2+ mg
Reports span 2 to ≥ 2 mg (open-ended top bucket)
2+ mg
6
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
Research
Cited research (3)
Source
PubMed
ARA 290 for treatment of small fiber neuropathy in sarcoidosis
van et al., 2014
PubMed
The time to develop treatments for diabetic neuropathy
Rendell, 2021
Tools
Explore more
Explore
More ways to learn about ARA-290 from observational PeptIQ data.
Compare with
Related peptides
Help
Frequently asked
What do PeptIQ users report about ARA-290?
This page summarizes 6 anonymized self-reports from PeptIQ users who track ARA-290, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for ARA-290?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for ARA-290?
3 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is ARA-290 safe to use?
This wiki does not assess safety or recommend use. ARA-290 is listed as Investigational (Phase 2). Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of ARA-290?
Research, primarily in animal models, suggests ARA-290 may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.
SourceWhat is the legal status of ARA-290?
ARA-290 is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified ARA-290 as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.
SourceWhat are the known or theoretical side effects and risks of ARA-290?
The safety and effectiveness of ARA-290 have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.
SourceWhat is the current state of research on ARA-290?
While there are over 200 published studies on ARA-290, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.
Source